First agent in a new class of noncytotoxic cancer drugs
Groundbreaking study paves way for targeted therapy
Novel drug could greatly improve patient outcomes
Opens new avenues for pharmacologic development
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Three clinical trials underway
Trial results reported for first molecularly targeted therapy
Proof-of-concept trial enrolling soon at Cleveland Clinic
Research improving myelodysplastic syndromes treatment
Correcting an irrational imbalance in oncotherapeutic care
Study finds redesigned low-dose decitabine regimen terminates cancer growth, produces durable benefits